Sitagliptin

Description

Sitagliptin · CAS 486460-32-6 · C16H15F6N5O. UNII QFP0P1DV7Z. Solubility: 3.40e-02 g/L; LogP: 1.5.

Identification

CAS Registry Number	486460-32-6
PubChem CID	4369359
Molecular formula	C16H15F6N5O
IUPAC name	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
UNII (FDA)	QFP0P1DV7Z

Computed Descriptors

Molecular Weight	407.31
XLogP3	0.7
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	4
Exact Mass	407.11807909
Monoisotopic Mass	407.11807909
Topological Polar Surface Area	77
Heavy Atom Count	28
Formal Charge	0

Physical & Chemical Properties

Solubility	3.40e-02 g/L
LogP	1.5

Physical description & handling notes

• Solid
• Viscous liquid
• Stable if stored as directed; avoid strong oxidizing agents. /Sitagliptin phosphate monohydrate/
• Thermal decomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides. /Sitagliptin phosphate monohydrate/
• MW: 523.32. White to off-white crystalline, non-hygroscopic powder. Soluble in water and N,N-dimethyl formamide; slightly soluble in methanol; very slightly soluble in ethanol, acetone, and acetonitrile; insoluble in isopropanol and isopropyl acetate. /Sitagliptin phosphate monohydrate/
• Sitagliptin inhibits DPP-4 which leads to increased levels of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide(GIP), decreased levels of glucagon, and a stronger insulin response to glucose.

Regulatory Status

GHS notification summary	2.4% (1 / 41)

GHS Hazard Classification

GHS notification summary	2.4% (1 / 41)
Reported hazard statements	H302 (92.7%), H318 (87.8%), H373 (95.1%)

Documented Uses

• Use (kg; approx.) in Germany (2009): >5000
• Consumption (g per capita; approx.) in Germany (2009): 0.0611
• Preparation: S. D. Edmondson et al, World Intellectual Property Organization patent 03004498; eidem, United States of America patent 6699871 (2003, 2004 both to Merck & Co).
• Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis. It is also used in combination with [metformin] or [ertugliflozin].
• Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. Only rare isolated reports of liver injury due to sitagliptin have been published.
• Breast Feeding; Lactation; Milk, Human; Hypoglycemic Agents; Incretins; Dipeptidyl-Peptidase IV Inhibitors; DPP-4 Inhibitors

Synonyms

Sitagliptin; 486460-32-6; Januvia; Zituvio; sitagliptina; sitagliptine; LEZ763; sitagliptinum; QFP0P1DV7Z; LEZ-763; CHEBI:40237; DTXSID70197572; ZITUVIMET COMPONENT SITAGLIPTIN; RefChem:6227; DTXCID30120063; 690-730-1

Frequently Asked Questions

What are the CAS number and molecular formula of Sitagliptin?

CAS 486460-32-6; molecular formula C16H15F6N5O; molecular weight — g/mol.

What other names is Sitagliptin known by?

Sitagliptin, 486460-32-6, Januvia, Zituvio, sitagliptina, sitagliptine.

Is Sitagliptin classified as hazardous?

2.4% of GHS notifications report no hazard classification (1 of 41).

What are the key physical properties of Sitagliptin?

Solubility: 3.40e-02 g/L; LogP: 1.5.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.